278650 — HLB BioStep Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for HLB BioStep Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	58,520	64,403	86,277	52,814	58,169
Cost of Revenue
Gross Profit	43,133	42,056	53,400	36,410	41,046
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	49,675	50,424	81,212	54,075	70,975
Operating Profit	8,845	13,979	5,065	-1,261	-12,806
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,471	12,827	-2,345	326	-11,528
Provision for Income Taxes
Net Income After Taxes	8,589	11,532	-883	-54.2	-9,693
Minority Interest
Net Income Before Extraordinary Items
Net Income	8,302	11,031	-1,008	-164	-8,564
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,302	11,031	-1,008	-164	-8,564
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	120	107	-1.65	-2.19	-100
Dividends per Share